Dermal Irritability Single High Dose Study of Ion Gel ZCM-25® on New Zealand Male Rabbits

• Related Articles

• Ion Gel ZCM-25® Phase 1 Clinical Study on Humans

  Abstract In the present Ion Gel ZCM-25® Phase 1 Clinical Study on Humans, the tolerability of the Class II Medical Device, Ion Gel ZCM-25® was evaluated after daily administration for 14 days, the dose of 0.5mL on the intact skin of the left arm of ...

• Ion Gel ZCM-25® in the Treatment of Lyme Disease Targeting Borrelia burgdorferi

  Background Lyme disease, caused by the spirochete bacterium Borrelia burgdorferi, transmitted through Ixodes tick bites, poses significant treatment challenges. Effective antimicrobial agents are essential for managing and mitigating this disease. ...

• Assessment of the Antifungal Efficacy of Ion Gel ZCM-25® Against Candida auris

  Background: Candida auris is an emerging fungal pathogen known for its resistance to conventional antifungal treatments. It is associated with high morbidity and mortality rates, particularly in healthcare environments. The development and evaluation ...

• Phase I study to determine the topical tolerability of Ion Gel ZCM-25®.

  To evaluate the tolerability of the product Ion Gel ZCM-25®, measured as the degree of irritability: edema and/or erythema, during 14 days of administration in healthy subjects. Methods. Twenty research subjects of both sexes were recruited, a dose ...

• Efficacy of Ion Gel ZCM-25® in the Antimicrobial Treatment Against Acinetobacter baumannii

  Background: Acinetobacter baumannii is a pathogenic bacterium responsible for a range of infections, particularly in healthcare settings, posing significant treatment challenges. The need for effective antimicrobial agents against Acinetobacter ...